Edition:
United States

Nattopharma ASA (NATTO.OL)

NATTO.OL on Oslo Stock Exchange

10.00NOK
7:02am EDT
Change (% chg)

kr-0.20 (-1.96%)
Prev Close
kr10.20
Open
kr10.00
Day's High
kr10.00
Day's Low
kr9.61
Volume
23,130
Avg. Vol
15,571
52-wk High
kr12.05
52-wk Low
kr6.50

Latest Key Developments (Source: Significant Developments)

NattoPharma Research Network receives EUR 4 mln research grant
Tuesday, 21 Mar 2017 03:45am EDT 

Nattopharma ASA : NattoPharma’s International Research Network, coordinated by the Cardiovascular Research Institute at Maastricht University (CARIM), has been awarded a second prestigious grant funded by the European Union within the Horizon 2020 Marie Skłodowska-Curie research and innovation program .Research Network receives 4 million euro ($4.31 million) research grant.  Full Article

Nattopharma named partner for EU research grant
Tuesday, 7 Feb 2017 02:21am EST 

Nattopharma ASA :Nattopharma named partner for EU research grant.  Full Article

Nattopharma Q3 EBITDA loss narrows to NOK 6.0 million
Wednesday, 16 Nov 2016 02:30am EST 

Nattopharma ASA : Q3 revenue rose by 76 pct to 10.8 million Norwegian crowns ($1.3 million) .Q3 EBITDA loss 6.0 million crowns versus loss 9.6 million crowns year ago.  Full Article

Nattopharma Q2 EBITDA loss narrows to 1.6 million crowns
Wednesday, 17 Aug 2016 02:30am EDT 

Nattopharma ASA : Q2 revenue rose by 73 pct to 13.3 million Norwegian crowns ($1.6 million) . Q2 EBITDA loss 1.6 million crowns versus loss 6.5 million crowns year ago .Expects that performance will continue to improve and maintain a positive EBITDA outlook in the quarters ahead.  Full Article

Novel Nutrition Network Sp z o.o. acquires 1.4 million Nattopharma shares
Tuesday, 19 Jul 2016 07:33am EDT 

Nattopharma ASA : Novel Nutrition Network Sp z o.o. buys 1.4 million shares in Nattopharma . Novel Nutrition Network Sp z o.o. acquires Nattopharma shares from Novel Nutrition Network Ltd .Total price was about 13.6 million Norwegian crowns ($1.60 million).  Full Article

Nattopharma awarded new patent for Vitamin K2
Tuesday, 14 Jun 2016 02:35am EDT 

Nattopharma ASA :Says has been awarded U.S. patent that allows company to claim that MK-7 inhibits or reduces incidence of age-related hardening of the arteries in individuals with cardiovascular conditions.  Full Article

Nattopharma: Karstein Gjersvik buys 823,586 shares in Nattopharma
Friday, 27 May 2016 09:04am EDT 

Nattopharma ASA : Karstein Gjersvik has via company KG Investment Comp AS bought 823,586 shares in Natto Pharma at 10 Norwegian crowns .After transaction Karstein Gjersvik's holding in Nattopharma is 2.2 million shares, corresponding to 13 percent of Nattopharma share capital.  Full Article

Nattopharma ASA COO Rosenbaum to become new CEO
Friday, 18 Dec 2015 12:43am EST 

Nattopharma ASA:Daniel Rosenbaum, who has been serving as COO of NattoPharma for the last 12 months, will assume the role of CEO.Hogne Vik, who has been serving in the role of CEO of NattoPharma since 2012, will assume the role of Chief Medical Officer.Kjetil Ramsøy will join the company, effective January 1, 2016, in the role of Chief Financial Officer.  Full Article

Nattopharma ASA in research network that receives EUR 2.9 mln grant
Wednesday, 9 Sep 2015 01:59am EDT 

Nattopharma ASA:Participates in research network that receives 2.9-million euros grant from European Commission's research program Horizon 2020-MSCA-ITN.The International Research Network is coordinated by Queen Mary University of London.  Full Article

Nattopharma selected preferred supplier partner by Mercola
Thursday, 20 Aug 2015 09:26am EDT 

Nattopharma ASA:Mercola selected Nattopharma as a preferred supplier partner.Mercola has included NattoPharma's MenaQ7 Vitamin K2 as MK-7 as a featured ingredient in the Dr. Mercola Premium Products line.  Full Article

More From Around the Web

BRIEF-NattoPharma Research Network receives EUR 4 mln research grant

* NattoPharma’s International Research Network, coordinated by the Cardiovascular Research Institute at Maastricht University (CARIM), has been awarded a second prestigious grant funded by the European Union within the Horizon 2020 Marie Skłodowska-Curie research and innovation program